This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| CF | |
|---|---|
| Name | Cystic fibrosis |
| Symptoms | Chronic cough; recurrent pulmonary infections; pancreatic insufficiency; failure to thrive |
| Complications | Bronchiectasis; liver disease; diabetes; infertility |
| Onset | Congenital |
| Causes | Mutations in CFTR gene |
| Diagnosis | Sweat chloride testing; genetic testing; nasal potential difference |
| Treatment | CFTR modulators; antibiotics; airway clearance; pancreatic enzyme replacement |
| Frequency | ~70,000–100,000 worldwide |
CF
Cystic fibrosis is an inherited autosomal recessive disorder characterized by dysfunction of an epithelial ion channel leading to viscous secretions, recurrent respiratory infections, malabsorption, and multisystem involvement. It results from pathogenic variants in a chloride and bicarbonate transport protein, with clinical care involving multidisciplinary teams including pediatricians, pulmonologists, gastroenterologists, and transplant surgeons. Advances in molecular diagnostics and precision therapeutics have transformed outcomes, while global disparities in diagnosis and treatment persist.
Terminology for the disorder includes classic and nonclassic designations, pancreatic-sufficient and pancreatic-insufficient phenotypes, and genotype classes I–VI based on underlying molecular defects. Historic eponyms and descriptive names arose in pediatric and surgical literature during the twentieth century, with nomenclature standardized by genetic and clinical consensus panels. Professional organizations such as the American Thoracic Society, European Respiratory Society, and Cystic Fibrosis Foundation have issued guidelines and position statements influencing diagnostic criteria, newborn screening protocols, and treatment algorithms.
Epidemiological prevalence varies by ancestry, with higher carrier frequencies reported in populations of Northern European descent and lower frequencies in East Asian and Sub-Saharan African populations. Newborn screening programs implemented across the United States, United Kingdom, France, Germany, Italy, Canada, Australia, and Scandinavia altered incidence estimates and age at diagnosis. The disorder is caused by mutations in a single gene encoding a transmembrane conductance regulator mapped to chromosome 7; over two thousand variants have been cataloged by databases maintained by research consortia and clinical laboratories. Founder mutations and population-specific alleles have been described in Ashkenazi Jewish, Irish, Icelandic, and Hispanic cohorts, informing screening panels and carrier testing strategies.
Pathophysiology centers on defective epithelial ion transport in airways, pancreas, biliary tract, reproductive tract, and sweat glands, resulting in dehydrated mucous secretions, impaired mucociliary clearance, and predisposition to chronic infection and inflammation. Molecular mechanisms include protein misfolding, defective trafficking, reduced channel gating, decreased conductance, and premature protein degradation, each linked to specific mutation classes described in molecular genetics literature. Secondary processes include neutrophil-dominated inflammation, biofilm formation by opportunistic pathogens, and progressive structural lung damage described in radiologic and pathologic studies.
Clinical manifestations span respiratory, gastrointestinal, hepatobiliary, endocrine, reproductive, and psychosocial domains. Respiratory features include persistent productive cough, recurrent otitis media, sinusitis, and bronchiectasis; notable pathogens include Staphylococcus aureus, Pseudomonas aeruginosa, Burkholderia cepacia complex, and non-tuberculous mycobacteria identified in infectious disease reports. Gastrointestinal presentation includes meconium ileus in neonates, steatorrhea, fat-soluble vitamin deficiency, and distal intestinal obstructive syndrome described in pediatric surgery literature. Fertility issues, notably congenital bilateral absence of the vas deferens, and complications such as CF-related diabetes and biliary cirrhosis are detailed in endocrinology and hepatology sources.
Diagnostic strategies combine newborn screening immunoreactive trypsinogen assays, targeted mutation panels, full gene sequencing, sweat chloride testing standardized by laboratory medicine authorities, and nasal transepithelial potential difference studies used in specialized centers. Diagnostic algorithms endorsed by national screening programs and metabolic disease networks guide confirmatory testing and variant interpretation. Multidisciplinary diagnostic evaluations often include radiology with high-resolution computed tomography, microbiology with culture and molecular pathogen detection, and nutritional assessment per pediatric gastroenterology protocols.
Management is multidisciplinary and includes airway clearance techniques, inhaled therapies, chronic suppressive and targeted antibiotics, mucolytics, anti-inflammatory agents, nutritional support with pancreatic enzyme replacement and vitamin supplementation, and hepatobiliary and endocrine management as indicated. Precision therapies targeting specific molecular defects—small-molecule modulators designed to correct folding, trafficking, or channel gating—have been developed through translational research and clinical trials supported by pharmaceutical and academic collaborations. Advanced care options include lung transplantation, biliary and intestinal surgeries, and assisted reproductive technologies coordinated by transplant centers and reproductive specialists. Guidelines from respiratory, pediatric, and gastroenterology societies inform surveillance, vaccination, and infection-control practices.
Prognosis has improved substantially with multidisciplinary care, population screening, and targeted therapies, with many patients now surviving into adulthood and pursuing employment and family life documented in longitudinal cohort studies. Complications include progressive bronchiectasis, respiratory failure, chronic bacterial colonization, CF-related diabetes mellitus, hepatic cirrhosis with portal hypertension, osteopenia and fractures, and psychosocial morbidity addressed in quality-of-life research. Registry data from national and international databases provide outcome metrics, transplant survival statistics, and healthcare utilization trends.
Active research areas include gene editing approaches, viral and nonviral gene delivery vectors, next-generation CFTR modulators, host-directed therapies to modulate inflammation, bacteriophage therapy and microbiome modulation, and biomarkers for early disease progression validated in multicenter trials. Collaborative networks involving academic centers, biotechnology firms, patient advocacy organizations, and public health agencies drive translational pipelines, regulatory submissions, and real-world evidence generation. Ongoing randomized trials and longitudinal registry studies aim to refine personalized medicine approaches and address disparities in access to novel therapeutics.
Category:Genetic disorders